文献速递肿瘤 PET/CT

高风险前列腺癌中金标准PSMA-PET/CT与⁶⁸Ga-FAPI及¹⁸F-FDG的多示踪剂比较:一项概念验证研究

Multitracer comparison of gold standard PSMA-PET/CT with 68Ga-FAPI and 18F-FDG in high-risk prostate cancer: a proof-of-concept study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-05-27

本研究纳入10例高风险前列腺癌患者,在根治性前列腺切除术前分别行[⁶⁸Ga]Ga-FAPI-46、[¹⁸F]F-/[⁶⁸Ga]Ga-PSMA和[¹⁸F]FDG PET/CT,并以病理为参考评估诊断准确性。结果显示[⁶⁸Ga]Ga-FAPI-46与PSMA示踪剂诊断准确性相当且优于[¹⁸F]FDG,MRI诊断准确性和局部分期优于所有示踪剂;FAP表达见于部分高风险患者,尤其高级别病变。

要点

  • 在10例高风险前列腺癌中,[⁶⁸Ga]Ga-FAPI-46与[¹⁸F]F-/[⁶⁸Ga]Ga-PSMA诊断准确性相当,且均优于[¹⁸F]FDG。
  • 全前列腺平均SUVmax以PSMA最高(13.1),FAPI次之(7.6),FDG最低(5.4),P=0.015。
  • MRI诊断准确性和局部分期优于所有受试放射性示踪剂。

核心结论

  • FAP表达见于部分高风险前列腺癌患者,尤其见于较高分级病变者。
  • 这项概念验证研究可能提示[⁶⁸Ga]Ga-FAPI-46 PET/CT在PSMA摄取低的分期原发性前列腺癌中具有一定作用,但需进一步研究以明确其临床应用。

研究设计与样本

  • 研究纳入10例高风险前列腺癌患者(PSA > 20 ng/mL、Gleason评分 > 7或 > T2c),在根治性前列腺切除术前接受[⁶⁸Ga]Ga-FAPI-46、[¹⁸F]F-/[⁶⁸Ga]Ga-PSMA和[¹⁸F]FDG PET/CT检查。
  • 对全前列腺及各个前列腺六分区测量SUVmax,按患者和按分区将影像所见与最终组织病理结果关联以评估诊断准确性。
  • 对指标肿瘤病灶行PSMA和FAP表达的免疫组化分析。

主要发现

  • 组织病理证实pT2c和pT3前列腺腺癌分别为4例(40%)和6例(60%),1例(10%)有区域淋巴结转移(pN1)。
  • 国际泌尿病理学会(ISUP)分级分组为2级60%、3级20%、5级20%。
  • 60个前列腺六分区中46个组织学阳性;PSMA表达在所有患者中均检出,FAP表达在9例中的5例(55.5%)检出。
  • 按患者和按分区分析显示,[⁶⁸Ga]Ga-FAPI-46与[¹⁸F]F-/[⁶⁸Ga]Ga-PSMA诊断准确性相当,且优于[¹⁸F]FDG。
  • 全前列腺平均(SD)SUVmax以PSMA PET/CT最高,为13.1(7),其次为FAPI 7.6(5.5),FDG 5.4(3.5)(P=0.015)。

局限性

  • 这项概念验证研究可能提示[⁶⁸Ga]Ga-FAPI-46 PET/CT在PSMA摄取低的分期原发性前列腺癌中具有一定作用,但需进一步研究以明确其临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to, evaluate the diagnostic accuracy of [⁶⁸Ga]Ga-FAPI-46 positron emission tomography (PET)/computed tomography (CT) in high-risk prostate cancer (PC) compared to [¹⁸F]PSMA / [⁶⁸Ga]Ga- PSMA- and [¹⁸F]FDG- PET/CT as well as multiparametric magnetic resonance imaging (MRI). MATERIALS AND METHODS: Ten patients with high-risk PC (PSA > 20 ng/mL, Gleason score > 7, or > T2c) underwent PET/CT imaging using [⁶⁸Ga]Ga-FAPI-46, [¹⁸F]F-/[⁶⁸Ga]Ga-PSMA and [¹⁸F]FDG before radical prostatectomy (RP). The maximum standardized uptake values (SUVmax) were measured for the entire prostate and individual prostate sextants. Diagnostic accuracy was assessed per patient and per segment by correlating imaging findings with final histopathologic results. Immunohistochemical analysis of PSMA and FAP expression was performed on the index tumor lesion. RESULTS: Histopathologic analysis confirmed pT2c and pT3 prostate adenocarcinoma in 4 (40%) and 6 (60%) patients, respectively. One patient (10%) had regional lymph node metastasis (pN1). The International Society of Urological Pathology (ISUP) grade groups (GGs) were 2 (60%), 3 (20%), and 5 (20%). Overall, 46 of 60 prostate sextants were histologically positive for PC. While PSMA expression was detected in all patients, FAP expression was observed in 5 of 9 cases (55.5%). Per-patient and per-segment analyses demonstrated that [⁶⁸Ga]Ga-FAPI-46 and [¹⁸F]F-/[⁶⁸Ga]Ga-PSMA had comparable diagnostic accuracy and outperformed [¹⁸F]FDG. The mean (SD) SUVmax of the entire prostate was highest for PSMA PET/CT at 13.1 (7), followed by FAPI at 7.6 (5.5) and FDG at 5.4 (3.5) (p = 0.015). Among patients in the FAPI subgroup, those with ISUP GG 3-5 exhibited greater FAP expression and radiotracer uptake compared to ISUP GG 2 cases. In the two high-grade patients, [⁶⁸Ga]Ga-FAPI-46 demonstrated greater tumor uptake than [¹⁸F]PSMA / [⁶⁸Ga]Ga-PSMA PET/CT. Notably, MRI demonstrated higher diagnostic accuracy and superior local staging compared to all radiotracers evaluated. CONCLUSION: FAP expression was detected in a subset of high-risk PC patients, particularly in those with higher-grade disease. This proof-of-concept study may suggest a role for [⁶⁸Ga]Ga-FAPI-46 PET/CT in primary PC with low PSMA avidity, but further research is warranted to define its clinical application.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Mahmoud O, Püllen L, Umutlu L, et al. Multitracer comparison of gold standard PSMA-PET/CT with 68Ga-FAPI and 18F-FDG in high-risk prostate cancer: a proof-of-concept study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40423777. doi:10.1007/s00259-025-07352-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。